



Docket No. CEN-269.1

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: ChiChang Lee, et al.

Serial No.: 10/003,632 Art Unit:

: November 2, 2001 Examiner: Filed

ENHANCED COMPOSITIONS FOR PROTEIN AND : METHODS For

EXPRESSION AND/OR GROWTH OF CULTURED CELLS CO-TRANSCRIPTION OF A Bc12 ENCODING NUCLEIC ACID

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, Washington, D.C. 20231 on

Guy Kevin Townsend (Name of applicant, assignee, or Registered Representative)

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Ŋ

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the aboveidentified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under \$1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action for the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required.

☐ In ac	ccordance w	vith §	1.129(a),	this Info	ormation	ı
Disclosure Stat	ement is b	eing	filed in	connectior	n with [] the
first or [seco	ond After F	inal	Submission	n, therefo	ore:	
	Statement	in Ac	cordance	with §1.9	7(e)	
	(attached)	; or				
	Please cha	arge I	eposit Ac	count No.	10-	
	0750/	/	the fee c	f \$180.00	as set	forth
	in §1.17(p	p).				

In accordance with §1.97(c), this Information
Disclosure Statement is being filed after the period set forth
in §1.97(b) above but before the mailing date of either a Final
Action under §1.113 or a Notice of Allowance under §1.311, or
an action that otherwise closes prosecution and that it is
accompanied by one of:

☐ State	ement in Accordance with §1.97(e)
(atta	ched); or
Pleas	se charge Deposit Account No. 10-
0750/	/ the fee of \$180.00 as set forth
in	§1.17(p).
☐ In accorda	nce with §1.97(d), this Information
Disclosure Statement	is being filed after the mailing date of
either a Final Actio	n under §1.113 or a Notice of Allowance
under §1.311 but be	fore the payment of the Issue Fee.
Applicant(s) hereby	petition(s) for consideration of this
Information Disclosu	re Statement. Included are: Statement in
Accordance with §1.9	7(e) as set forth below and the fee of
\$180.00 as set forth	in §1.17(p).
	each of the references listed on the
attached Form PTO-14	49 are enclosed herewith.
Copies of 1449 are enclosed he	references listed on the attached Form PTO rewith EXCEPT THAT:
[list	new of the voluminous nature of references as appropriate, and the likelihood that references are available to the Examiner, are not enclosed herewith.
avai	ny of the foregoing publications are not lable to the Examiner, Applicant will avor to supply copies at the Examiner's est.
There are	no listed references which are not in the

English language.

The relevance of those listed references which are not in the English language is as follows:
Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.
Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.
Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN269.1/GKT. This form is submitted in triplicate.
Respectfully submitted,
Guy Kevin Townsend Reg. No. 34,033 Attorney for Applicants
Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
. (732) 524-2617
DATED:

V

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

Application Number	10/003,632
Filing Date	November 2, 2001
First Named Inventor	ChiChang Lee, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN-269.1

U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication Pages, Columns, Lines, Name of Patentee or Applicant Kind Code² Examiner Cite of Cited Document where relevant passages of Cited Document Initials Number (if known) or relevant figures appear No.1 mm-dd-yyyy

FOREIGN PATENT DOCUMENTS Foreign Patent Document **Date of Publication** Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or Examiner Cite passages or relevant Te mm-dd-yyyy **Applicant of Cited Document** Initials figures appear Office³ Number⁴ KindCode⁵ No.1 JP 9163983 Hisamitsu Pharma.Co. Ltd 05-24-1997 X

Examiner	Date	
Signature	Considered	

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

& TRADEStitute for form 1449A/PTO

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

	" (C)
Application Number	10/003,632
Filing Date	November 2, 2001
First Named Inventor	ChiChang Lee, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN-269.1

***		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T
Initials*	No. ¹	publisher, city and/or country where published	
		E. Suzuki, "Establishing apoptosis resistant cell lines for improving protein productivity of cell culture", CYPOTECHNOLOGY, vol. 23, 1997, pages 55-59, XP 001009825	
		Database WPI week 9735, Derwent Publications Ltd., London, GB, An 1997-380167 XP002208597	
		N. Kim et al., "Overexpression of blcl-2 inhibits sodium butyrate-induced apoptosis in Chinese hamster ovary cells resulting in enhanced humanized antibody production.", BIOTECHNOLOGY AND BIOENGINEERING, vol. 71, no. 3, 2000, pages 184-193, XP002208594, New York NY	
		B. Tey et al.: "Influence of bcl-2 on cell death during the cultivation of a Chinese hamster ovary cell line expressing a chimeric antibody." BIOTECHNOLOGY AND BIOENGINEERING, vol. 6, no. 1, 5 April 2000, pages 31-43, XP002208595, New York, NY	
		N. Simpson et al, "Prevention of hybridoma cell death by bcl-2 during suboptimal culture conditions." BIOTECHNOLOGY AND BIOENGINEERING, vol. 54, no. 1, 1997, pages 1-16, XP002208596	
		D. Fassnacht et al:, "Influence of bcl-w on antibody productivity in high cell density perfusion cultures of hybridoma." CYTOTECHNOLGOY, vol. 30, no. 1-3, 1999, pages 95-105, XP001009822	
	,		
	,		

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

OT PE JONE 27 200 PERSON & TRADCLINING

SUBMISSION UNDER MPEP 609 D

Application Number	10/003,632
Filing Date	November 2, 2001
First Named Inventor	ChiChang Lee, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	CEN 269.1

Page 1 of 1

Examiner Initials No.1 Name of Patentee or Applicant of Cited Document Of Cited Document Number (if known) Pages, Columns, Lines, where relevant passages or relevant figures appear

FOREIGN PATENT DOCUMENTS Foreign Patent Document Pages, Columns, Lines, where relevant passages Name of Patentee or or relevant figures Examiner Cite Applicant of Cited Document Office³ Number⁴ Initials KindCode⁵ appear No.1 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Cite No.¹ Examiner T² Initials* International Search Report for application No. PCT/US01/45553 dated August 16, 2002

Examiner	Date	
Signature	Considered	